GSK Pays $10.6 Billion to Acquire Lung Cancer Specialist Nuvalent

Major Biotech Acquisition Signals GSK's Oncology Ambitions

GlaxoSmithKline delivered a powerful statement about its cancer treatment strategy on June 9, announcing a $10.6 billion acquisition of Nuvalent Inc. , a Boston-based biotech company specializing in precision lung cancer therapies. The deal values Nuvalent at $124 per share in cash, representing a 40% premium over the company's Monday closing price .

The acquisition marks the first major transaction for GSK CEO Luke Miels and represents GSK's largest acquisition in over a decade . This multi-product oncology deal aligns with GSK's strategy of investing in validated, differentiated science and accelerates the company's entry into lung cancer .

Promising Pipeline with Near-Term Revenue Potential

Nuvalent brings three compelling cancer treatments to GSK's portfolio. The crown jewels are zidesamtinib (NVL-520) and neladalkib (NVL-655), two late-stage, next-generation inhibitors targeting ROS1 and ALK proteins in non-small cell lung cancer, both having received FDA Breakthrough Therapy and Orphan Drug Designations .

These treatments are currently under FDA review with target decision dates of September 18, 2026 for zidesamtinib and November 27, 2026 for neladalkib . Subject to FDA approval, both drugs are expected to launch in 2026 and have multi-blockbuster potential . The third asset, NVL-330, is a potential best-in-class HER2 inhibitor currently in phase I trials .

Strategic Response to Patent Pressures

The acquisition aligns with GSK's strategy of acquiring assets that have validated targets and meaningfully address efficacy and tolerability limitations of existing standard-of-care therapies . Analysts note that the high acquisition price reflects GSK's urgent response to pressures from patent expirations affecting its leading products .

After accounting for Nuvalent's cash position, GSK's net investment totals approximately $9.4 billion . The deal creates synergies with GSK's existing oncology assets, particularly providing a platform for expansion with Ris-Rez, GSK's B7-H3 antibody-drug conjugate .

Financial Impact and Future Outlook

GSK expects the acquisition to deliver measurable financial benefits relatively quickly. The company projects the deal will be accretive to sales and core operating profit in 2027 and core earnings per share in 2029, inclusive of synergies and reprioritization .

This transaction positions GSK to compete more aggressively in the lucrative oncology market while addressing immediate revenue needs. Under the merger agreement, GSK will commence a tender offer within 10 business days , signaling the company's eagerness to integrate these promising cancer treatments into its portfolio and accelerate their path to patients who need them most.